X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16963) 16963
Book Review (1403) 1403
Publication (458) 458
Newsletter (295) 295
Magazine Article (25) 25
Conference Proceeding (24) 24
Newspaper Article (12) 12
Transcript (12) 12
Book Chapter (11) 11
Dissertation (5) 5
Trade Publication Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14623) 14623
humans (13518) 13518
male (9018) 9018
prednisolone - administration & dosage (8848) 8848
female (8756) 8756
adult (5730) 5730
middle aged (5599) 5599
prednisolone - therapeutic use (4939) 4939
prednisolone (4717) 4717
aged (3558) 3558
treatment outcome (2863) 2863
adolescent (2443) 2443
drug therapy, combination (2409) 2409
corticosteroids (2389) 2389
animals (2361) 2361
child (1767) 1767
glucocorticoids - administration & dosage (1734) 1734
antineoplastic combined chemotherapy protocols - therapeutic use (1711) 1711
administration, oral (1688) 1688
cyclophosphamide - administration & dosage (1628) 1628
prednisolone - adverse effects (1569) 1569
anti-inflammatory agents - administration & dosage (1555) 1555
abridged index medicus (1551) 1551
glucocorticoids - therapeutic use (1462) 1462
time factors (1446) 1446
vincristine - administration & dosage (1446) 1446
anti-inflammatory agents - therapeutic use (1357) 1357
follow-up studies (1272) 1272
prednisolone - pharmacology (1251) 1251
drug administration schedule (1227) 1227
therapy (1210) 1210
child, preschool (1081) 1081
steroids (1067) 1067
doxorubicin - administration & dosage (1046) 1046
dose-response relationship, drug (1015) 1015
retrospective studies (963) 963
rats (928) 928
care and treatment (925) 925
oncology (916) 916
immunosuppressive agents - therapeutic use (907) 907
medicine, general & internal (904) 904
pharmacology & pharmacy (894) 894
prognosis (893) 893
immunosuppressive agents - administration & dosage (881) 881
medicine & public health (864) 864
remission induction (846) 846
administration, topical (843) 843
dosage and administration (831) 831
drug therapy (812) 812
recurrence (812) 812
rheumatology (809) 809
hematology (785) 785
pediatrics (781) 781
aged, 80 and over (778) 778
glucocorticoids (775) 775
prospective studies (757) 757
surgery (751) 751
methylprednisolone - administration & dosage (744) 744
children (738) 738
diagnosis, differential (702) 702
ophthalmology (698) 698
risk factors (689) 689
prednisolone - analogs & derivatives (687) 687
infant (683) 683
immunology (669) 669
combined modality therapy (650) 650
disease (646) 646
research (642) 642
biopsy (627) 627
analysis (625) 625
antineoplastic combined chemotherapy protocols - administration & dosage (615) 615
transplantation (611) 611
double-blind method (603) 603
acute disease (593) 593
diagnosis (581) 581
asthma - drug therapy (578) 578
glucocorticoids - adverse effects (576) 576
health aspects (576) 576
chemotherapy (572) 572
dexamethasone (570) 570
young adult (565) 565
methotrexate - administration & dosage (555) 555
dermatology (543) 543
mice (541) 541
prednisone - administration & dosage (521) 521
severity of illness index (519) 519
gastroenterology & hepatology (515) 515
inflammation (491) 491
azathioprine - administration & dosage (481) 481
magnetic resonance imaging (479) 479
arthritis, rheumatoid - drug therapy (463) 463
methylprednisolone (463) 463
patients (456) 456
management (453) 453
rituximab (450) 450
dexamethasone - administration & dosage (447) 447
antineoplastic combined chemotherapy protocols - adverse effects (442) 442
cyclophosphamide (442) 442
injections, intravenous (435) 435
urology & nephrology (434) 434
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13557) 13557
Japanese (1875) 1875
German (766) 766
Russian (531) 531
French (167) 167
Spanish (61) 61
Italian (58) 58
Polish (50) 50
Chinese (44) 44
Danish (44) 44
Hungarian (20) 20
Norwegian (19) 19
Portuguese (19) 19
Swedish (19) 19
Dutch (18) 18
Ukrainian (15) 15
Korean (10) 10
Bulgarian (9) 9
Lithuanian (7) 7
Turkish (6) 6
Finnish (5) 5
Hebrew (5) 5
Romanian (5) 5
Croatian (3) 3
Serbian (2) 2
Czech (1) 1
Greek (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2011, Volume 22, Issue 3, pp. 664 - 670
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2012, Volume 23, Issue 5, pp. 1267 - 1273
To describe incidence, risk factors, and influence of treatment on occurrence of central nervous system (CNS) relapse or progression in younger patients with... 
Rituximab | Central nervous system relapse | DLBCL | Aggressive lymphoma | RISK-FACTORS | LEPTOMENINGEAL DISEASE | FOLLOW-UP | central nervous system relapse | NATURAL-HISTORY | aggressive lymphoma | STUDY-GROUP DSHNHL | ONCOLOGY | DOSE-ESCALATED CHOEP | CENTRAL-NERVOUS-SYSTEM | FLOW-CYTOMETRY | ELDERLY-PATIENTS | rituximab | Doxorubicin - therapeutic use | Prednisolone - adverse effects | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Cyclophosphamide - adverse effects | Lymphoma, Non-Hodgkin - pathology | Medical Oncology - organization & administration | Societies, Medical - organization & administration | Young Adult | Clinical Trials, Phase III as Topic - statistics & numerical data | Clinical Trials, Phase II as Topic - statistics & numerical data | Vincristine - administration & dosage | Prednisone - adverse effects | Etoposide - administration & dosage | International Cooperation | Central Nervous System Neoplasms - epidemiology | Lymphoma, B-Cell - epidemiology | Germany - epidemiology | Methotrexate - adverse effects | Adolescent | Age of Onset | Vincristine - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Prednisone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - therapeutic use | Central Nervous System Neoplasms - secondary | Multicenter Studies as Topic | Neoplasm Grading | Adult | Female | Prednisolone - therapeutic use | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Neoplasm Invasiveness | Etoposide - therapeutic use | Lymphoma, Non-Hodgkin - epidemiology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell - pathology | Doxorubicin - adverse effects | Index Medicus | B-cell lymphoma | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1250 - 1259
Journal Article
Pediatric Blood and Cancer, ISSN 1545-5009, 03/2007, Volume 48, Issue 3, pp. 254 - 261
Background. Adolescents with acute lymphoblastic leukaemia (ALL) have languished in the shadow of success of the outcome of therapy in childhood ALL. Their... 
Treatment outcome | Acute lymphoblastic leukemia | Survival | Adolescent | Young adult | YOUNG-ADULTS | MAINTENANCE CHEMOTHERAPY | RANDOMIZED-TRIALS | PROTOCOLS | survival | young adult | INDUCTION | treatment outcome | CHILDHOOD | CONSOLIDATION | THERAPY | ONCOLOGY | acute lymphoblastic leukemia | TERM FOLLOW-UP | adolescent | PEDIATRICS | CHILDRENS CANCER GROUP | HEMATOLOGY | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Prognosis | Age Factors | Humans | Male | Transplantation, Autologous | Transplantation, Homologous | Patient Selection | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Bone Marrow Transplantation | Vincristine - administration & dosage | Female | Daunorubicin - administration & dosage | Randomized Controlled Trials as Topic - statistics & numerical data | Dexamethasone - administration & dosage | Mercaptopurine - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cranial Irradiation | Remission Induction | Cytarabine - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Thioguanine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Methotrexate - administration & dosage | Research Design | Index Medicus
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report... 
Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Hodgkin's lymphoma | dexamethasone | refractory disease | THERAPY | thalidomide | RECURRENT | transplantation | DISEASE | cyclophosphamide | VINBLASTINE | PATIENT | HEMATOLOGY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9806, pp. 1858 - 1867
Summary Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESPONSE CRITERIA | AGGRESSIVE LYMPHOMAS | POOR-PROGNOSIS | NON-HODGKINS-LYMPHOMA | REGIMEN | YOUNG-PATIENTS | ELDERLY-PATIENTS | DES-LYMPHOMES | TRANSPLANTATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Vindesine - adverse effects | Adult | Female | Prednisolone | Doxorubicin - administration & dosage | Severity of Illness Index | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Risk Assessment | Rituximab | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Vincristine | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Adolescent | Survival Analysis | Vindesine - administration & dosage | Doxorubicin - adverse effects | Chemotherapy | Physiological aspects | Lymphomas | B cells | Drug therapy | Methods | Cancer | Dehydrogenases | Toxicity | Population studies | Doxorubicin | Hepatitis | Randomization | Bleomycin | Motivation | Drug dosages | Neutropenia | Cell survival | Hematology | Prednisone | Survival | Patients | Lymphoma | Cyclophosphamide | Lymphocytes B | Monoclonal antibodies | CD20 antigen | Tumors | B-cell lymphoma | Clinical trials | Public speaking | Grants | Clinical medicine | Index Medicus | Abridged Index Medicus | Side effects | lymphoma | survival | International standardization | chemotherapy
Journal Article
Pediatric Cardiology, ISSN 0172-0643, 10/2005, Volume 26, Issue 5, pp. 595 - 600
Cardiopulmonary bypass (CPB) is associated with a systemic inflammatory response. Pre-bypass steroid administration may modulate the inflammatory response,... 
Cardiopulmonary bypass | Medicine & Public Health | Cardiac Surgery | Glucocorticoids | Vascular Surgery | Congenital heart disease | Inflammation | Cardiology | DEXAMETHASONE | COMPLEMENT | CARDIAC & CARDIOVASCULAR SYSTEMS | BYPASS-INDUCED INFLAMMATION | INJURY | ADHESION MOLECULES | METHYLPREDNISOLONE | inflammation | congenital heart disease | cardiopulmonary bypass | PEDIATRICS | glucocorticoids | CORTICOSTEROIDS | APROTININ | EXPRESSION | Prednisolone - administration & dosage | Prospective Studies | Heart Defects, Congenital - surgery | Cardiopulmonary Bypass - adverse effects | Humans | Neutrophils - drug effects | Child, Preschool | Infant | Treatment Outcome | Biomarkers - blood | Systemic Inflammatory Response Syndrome - blood | C-Reactive Protein - metabolism | Creatinine - blood | Systemic Inflammatory Response Syndrome - prevention & control | Anti-Inflammatory Agents - administration & dosage | Systemic Inflammatory Response Syndrome - etiology | C-Reactive Protein - drug effects | Cardiac Surgical Procedures - methods | Leukocyte Count | Interleukin-8 - blood | Neutrophils - metabolism | Systemic Inflammatory Response Syndrome - drug therapy | Heart Defects, Congenital - blood | Heart | Complications and side effects | Surgery | Causes of | Dosage and administration | Research | Drug therapy | Steroids (Drugs) | Index Medicus
Journal Article
Otology & Neurotology, ISSN 1531-7129, 02/2017, Volume 38, Issue 2, pp. 272 - 277
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2008, Volume 26, Issue 28, pp. 4587 - 4594
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2017, Volume 178, Issue 5, pp. 772 - 780
We compared the efficacy and safety of gemcitabine, cisplatin, prednisone and thalidomide ( GDPT ) with standard CHOP regimen (cyclophosphamide, doxorubicin,... 
GDPT | peripheral T‐cell lymphoma | chemotherapy | safety | efficacy | peripheral T-cell lymphoma | SURVIVAL | DEXAMETHASONE | REGIMEN | TRIAL | DRUGS | NON-HODGKIN-LYMPHOMA | THERAPIES | HEMATOLOGY | LONG | Prednisolone - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, T-Cell, Peripheral - metabolism | Biomarkers, Tumor - metabolism | Vincristine - administration & dosage | Adult | Deoxycytidine - adverse effects | Female | Gene Expression Regulation, Neoplastic - drug effects | Doxorubicin - administration & dosage | Thalidomide - adverse effects | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Deoxycytidine - administration & dosage | RNA, Messenger - genetics | Lymphoma, T-Cell, Peripheral - genetics | Treatment Outcome | Thalidomide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Cisplatin - adverse effects | RNA, Neoplasm - genetics | Vincristine - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Doxorubicin - adverse effects | Antimitotic agents | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Prednisone | Non-Hodgkin's lymphomas | Antineoplastic agents | T cells | Biological markers | Steroids | Cancer | Therapy | Gemcitabine | Toxicity | Lymphocytes T | Gene expression | Survival | Patients | Doxorubicin | Vincristine | Lymphoma | Cisplatin | Cyclophosphamide | Biomarkers | ERCC1 protein | Remission | Lymphomas | Bioindicators | Safety | Thalidomide | T-cell lymphoma | Acute toxicity | Index Medicus
Journal Article